OncoMatch/Clinical Trials/NCT06208657

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Is NCT06208657 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Paxalisib and Opdualag for childhood cancer.

Phase 1/2RecruitingAustralian & New Zealand Children's Haematology/Oncology GroupNCT06208657Data as of Jun 2026Location: Australia · Canada

Treatment: Paxalisib · Opdualag · Irinotecan (drug) · Temozolomide (TMZ) — A companion platform trial to test novel targeted agents based on the patient's tumor profile.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Opdualag

Chemotherapy

Irinotecan (drug)

Other

PaxalisibTemozolomide (TMZ)

Cancer type

Tumor Agnostic

Glioblastoma

Demographics

Ages 0–21

Lab requirements

Blood counts

Adequate organ function

Kidney function

Adequate organ function

Liver function

Adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06208657 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 21 years or younger and at least 0 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Glioblastoma trials